Research, Select, & Monitor Saturday, May 30, 2020 5:31:26 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
Immunomedics, Inc.$33.59$.29.87%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Immunomedics, Inc. vs Diagnostic Substances

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.

Be they in the hardware development side or the chemical development side, these companies have the same goal; to increase the disease detection threshold and to increase the productivity of labs so more tests can be performed in less time. Each company tends to go about this goal in a different way. One company is involved heavily in gene testing and therapy, another is in manufacturing better isotopes to be used in nuclear medicine. Also, some companies have their hand in the home-testing fields for such things as Human Immunodeficiency Virus (HIV, the virus that causes AIDS) and other diseases.
 Totals Company Industry
  Sales: $0.3 Mil $14,090.8 Mil
  Market Cap: $7,163.0 Mil $140,034.5 Mil
  Analysts Recommendation: Strong Buy Buy

 Averages Company Industry
  Historic Revenue: N/A (5.0%)
  Estimated Revenue: 29,436.7% 2,256.5%
  Historic Earnings: N/A 33.5%
  Estimated Earnings: N/A 44.8%
  Stock Price (1 Year): 139.2% 49.5%
  Cash per Share: 21.6% (8.5%)
  Dividend: N/A N/A
  Trailing PE: N/A N/A
  Forward PE: N/A 42.6
  Price-to-Sales: 23,992.9 N/A
  Price-to-Book: 24.3 7.3
  Dividend Yield: N/A N/A
  Market Cap: $7,163.0 Mil $7,001.7 Mil
  Net Margin: (123,016.9%) (8,257.1%)
  Gross Margin: 100.0% 10.2%
  Return on Equity: (1.3) (.4)
  Return on Assets: (.5) (.2)
  Balance Sheet
  Current Ratio: 8.9 5.3
  Quick Ratio: 8.9 4.7
  Cash Ratio: 8.5 3.1
  Debt-to-Equity: 1.5 2.6
  Interest Coverage: .2 .9
  Relative-Strength Index: 72.7 N/A

 Other companies in Diagnostic Substances Price Market Cap
  Edwards Lifesciences Corp.  (EW) $224.72 $47,573.2 Mil
  DexCom Inc  (DXCM) $378.31 $35,599.0 Mil
  IDEXX Laboratories, Inc.  (IDXX) $308.88 $26,781.4 Mil
  Quidel Corporation  (QDEL) $175.00 $7,595.5 Mil
  Wright Medical Group Inc.  (WMGI) $29.55 $3,804.4 Mil

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2020 All rights reserved.